Fusion Antibodies Full Year 2024 Earnings: EPS Misses Expectations

Fusion Antibodies (LON:FAB) Full Year 2024 Results

Key Financial Results

• Revenue: UK£1.14m (down 61% from FY 2023).
• Net loss: UK£2.23m (loss narrowed by 14% from FY 2023).
• UK£0.039 loss per share (improved from UK£0.10 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fusion Antibodies EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 26%.

The company's shares are up 6.5% from a week ago.

Risk Analysis

Be aware that Fusion Antibodies is showing 6 warning signs in our investment analysis and 4 of those are a bit unpleasant...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.